You are a medicinal-chemistry and Parkinson's disease (PD) drug-discovery expert acting as a therapeutic-discovery assistant. Evaluate a small-molecule candidate as a PD therapeutic.

### Therapeutic context
- **Disease context:** idiopathic Parkinson's disease, targeting **α-synuclein aggregation** (oligomer/fibril formation central to Lewy pathology). This is a CNS indication — the drug must reach the brain.
- **Candidate:** "Compound S1", an anle138b-like diaryl-pyrazole proposed as an **α-synuclein aggregation modulator** (inhibits formation/propagation of pathogenic oligomers).
- **SMILES:** `Brc1cccc(c1)-c1cc(-c2ccc3OCOc3c2)[nH]n1`
- **Proposed target / MoA:** binds aggregation-prone α-synuclein species / interferes with oligomer formation rather than a classical enzyme/receptor pocket — a **non-classical, hard-to-quantify target engagement**.
- **Provided profile:** good predicted CNS penetration (low MW, lipophilic, low TPSA); in vitro reduction of α-synuclein aggregation and reduced pathology in α-synuclein-overexpressing mouse models; **no validated clinical target-engagement biomarker**.

### Your job
Assess whether this candidate should progress. Reason explicitly through:
1. PD disease relevance (α-synuclein aggregation → Lewy pathology / spreading).
2. Target / MoA plausibility for an **aggregation modulator**, and the difficulty of defining and measuring target engagement for an anti-aggregation mechanism (no clean binding pocket; biomarker challenge).
3. Binding/aggregation evidence (if you generate any) and its interpretation.
4. Blood–brain barrier (BBB) penetration — this is a CNS target.
5. ADMET risks: solubility, metabolic stability/clearance, CYP liability, hERG, AMES, DILI.
6. The **translational risk** that anti-aggregation small molecules have repeatedly shown preclinical promise but uncertain clinical efficacy, and that proof of mechanism in humans is hard.
7. Patent / novelty risk.
8. A Go / No-Go / Conditional Go decision.
9. The single most informative next experiment (e.g. developing/validating a target-engagement or pathology biomarker, PET ligand, or seeding assay readout).

Critically distinguish **mechanistic plausibility and preclinical pathology effects** from **proven disease modification**, and treat the **target-engagement/biomarker gap** as a central uncertainty rather than glossing over it.

### Available tools
Pharmacology tools (ADMET, physicochemical properties, docking/binding affinity, repurposing KG), databases (OpenTargets, Monarch, ClinVar, GWAS, ChEMBL/GtoPdb, clinical trials, FDA safety), literature/web search, and `run_python_repl`. Use them to ground the α-synuclein-aggregation rationale and prior anti-aggregation programs. Cite what you used.

### Deliverables (write to the run's output directory)
> **Output path:** `output_dir` is already defined in `run_python_repl` and points to your run directory. Do **not** reassign it or invent a path (e.g. `output_dir = "output/..."`). Write exactly to `f"{output_dir}/result.json"` and `f"{output_dir}/reasoning.txt"`.
- **`result.json`** — a JSON object matching the `small_molecule` output schema in `tasks/pdtx/schemas/output_schema_v2.json`. Required keys: `mechanism_hypothesis`, `admet_assessment` (with `bbb`, `ames`, `herg`, `dili`, `cyp_risk`, `solubility`, `clearance`), `go_no_go` (one of `Go`/`No-Go`/`Conditional Go`), `main_risks`, `next_experiment`, `confidence` (0–1). Include `target_relevance`, `docking_interpretation`, `patent_risk`, `uncertainty`, and `evidence_used` where possible. Generate the file programmatically; do not hand-write it.
- **`reasoning.txt`** — ~150-word write-up of the analyses behind your decision, including how you handled uncertainty.
